Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C

AIDS Research and Human Retroviruses

Volumn 26, Issue 4, 2010, Pages 419-424

  Vispo, Eugenia ^a   Labarga, Pablo ^a   Guardiola, Josep M ^b   Barreiro, Pablo ^a   Miralles, Celia ^c   Rubio, Rafael ^d   Miralles, Pilar ^e   Aguirrebengoa, Koldo ^f   Portu, Joseba ^g   Morello, Judit ^a   Rodriguez Novoa, Sonia ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL XERAL CÍES   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g HOSPITAL TXAGORRITXU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ERYTHROPOIETIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEMOGLOBIN DETERMINATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; EPOETIN ALFA; ERYTHROCYTES; FEMALE; HEMATINICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77951827268     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0120     Document Type: Article

References (34)

1. Rockstroh J, Mocroft A, Soriano V, et al.: Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992-1002.
2. Weber R, Sabin C, Friis-Moller N, et al.: Liver-related deaths in persons infected with the HIV: The D:A:D study. Arch Intern Med 2006;166:1632-1641.
3. Rosenthal E, Pialoux G, Bernard N, et al.: Liver related mortality in HIV-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 2007;14:183-188.
4. Soriano V, Puoti M, Sulkowski M, et al.: Care of patients coinfected with HIV and hepatitis C virus: 2007 recommendations from the HCV-HIV International Panel. AIDS 2007;21:1073-1089.
5. Rockstroh J, Bhagani S, Benhamou Y, et al.: European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82-88.
6. Chung R, Andersen J, Volberding P, et al.: Peginterferon alfa- 2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459.
7. Torriani F, Rodriguez-Torres M, Rockstroh J, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351: 438-450. (Pubitemid 38988593)
8. Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa- 2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004;292:2839-2848.
9. Nunez M, Miralles C, Berdun MA, et al.: Role of weightbased ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972-982.
10. Manns M, McHutchison J, Gordon S, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-965. (Pubitemid 32913521)
11. Fried M, Shiffman M, Reddy K, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
12. Zeuzem S, Berg T, Moeller B, et al.: Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009;16:75-90.
13. Ramos B, Nunez M, Rendon A, et al.: Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV=HIV-coinfected patients. J Viral Hepat 2007;14:387-391.
14. Shiffman M, Salvatore J, Hubbard S, et al.: Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin and epoetin alpha. Hepatology 2007;46:371-379.
15. Hadziyannis S, Sette H, Morgan T, et al.: Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:1437-1444.
16. Jacobson I, Brown R, Freilich B, et al.: Peginterferon alpha-2b and weight-based or flat dose ribavirin in chronic hepatitis C patients: A randomized trial. Hepatology 2007;46:971-981.
17. Nunez M, Camino N, Ramos B, et al.: Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther 2005;10:657-662.
18. McHutchison J, Manns M, Patel K, et al.: Adherence to combination therapy enhances sustained response in genotype- 1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.
19. Reddy K, Shiffman M, Morgan T, et al.: Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alpha-2a=ribavirin treatment. Clin Gastroenterol Hepatol 2007;5:124-129.
20. Afdhal N, Dieterich D, Pockros P, et al.: Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-1311.
21. Lindahl K, Stahle L, Bruchfeld A, and Schvarcz R: High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005;41:275-279.
22. Fried M, Jensen D, Rodriguez-Torres M, et al.: Improved outcomes in HCV patients with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008;48:1033-1043.
23. Morello J, Rodriguez-Novoa S, Rendon A, Gonzalez-Pardo G, Jimenez-Nacher I, and Soriano V: Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Ther Drug Monitor 2007;29:802-806.
24. Martin-Carbonero L, Nuñez M, Mariño A, et al.: Undetectable hepatitis C virus RNA at week 4 as a predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008;22:15-21.
25. Soriano V, Mocroft A, Rockstroh J, et al.: Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008;198:1337-1344.
26. Jen J, Glue P, Gupta S, Zambas D, and Hajian G: Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000;22:555-565.
27. Maynard M, Pradat P, Gagnieu MC, Souvignet C, and Trepo C: Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008;13:607-611.
28. Breilh D, Foucher J, Castéra L, et al.: Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2009;30:487-494.
29. Dixit N, Layden-Almer J, Layden T, and Perelson A: Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004;432:922-924.
30. Jarvis S, Thorn J, and Glue P: Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosinesensitive (es)-nucleoside transporters. Br J Pharmacol 1998;123:1587-1592.
31. De Franceschi L, Fattovich G, Turrini F, et al.: Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology 2000;31:997-1004.
32. Russmann S, Grattagliano I, Portincasa P, Palmieri V, and Palasciano G: Ribavirin-induced anemia: Mechanisms, risk factors and related targets for future research. Curr Med Chem 2006;13:3351-3357.
33. Laskin O, Longstreth J, Hart C, Scavuzzo D, Kalman C, Connor J, and Roberts R: Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987;41:546-555. (Pubitemid 17074331)
34. Govindarajan R, Endres C, Whittington D, et al.: Expression and hepatobilliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwichcultured human hepatocytes. Am J Physiol Gastrointest Liver Physiol 2008;295:570-580.